Risk of Preeclampsia in Human Immunodeficiency Virus-Infected Pregnant Women

被引:46
|
作者
Sansone, Matilde
Sarno, Laura
Saccone, Gabriele
Berghella, Vincenzo
Maruotti, Giuseppe Maria
Migliucci, Annalisa
Capone, Angela
Martinelli, Pasquale [1 ]
机构
[1] Univ Naples Federico II, Sch Med, Dept Neurosci Reprod Sci & Dent, Via Pansini 5, I-80128 Naples, Italy
来源
OBSTETRICS AND GYNECOLOGY | 2016年 / 127卷 / 06期
关键词
ANTIRETROVIRAL THERAPY; HIV;
D O I
10.1097/AOG.0000000000001424
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE:To evaluate the risk of preeclampsia in pregnant women with human immunodeficiency virus (HIV).METHODS:This is a 26-year population-based retrospective cohort study. Human immunodeficiency virus-infected pregnant women were compared with a HIV-negative comparison group. The primary outcome was the incidence of preeclampsia. We planned subgroup analysis according to antiretroviral therapy.RESULTS:A total of 84,725 women were included in the analysis, of whom 453 were HIV-infected and 84,272 HIV-negative. Of the 453 HIV-infected women, 301 (66.4%) received highly active antiretroviral therapy (HAART group) during pregnancy, whereas 152 (33.6%) did not. After adjusting for confounders, we found that HIV-infected women had a significantly higher risk of preeclampsia (10.2% compared with 4.1%; adjusted odds ratio [OR] 2.68, 95% confidence interval [CI] 1.96-3.64), preeclampsia with severe features (4.0% compared with 2.0%; adjusted OR 2.03, 95% CI 1.26-3.28), early-onset (3.5% compared with 1.4%; adjusted OR 2.50, 95% CI 1.51-4.15) and late-onset preeclampsia (6.6% compared with 2.6%; adjusted OR 2.64, 95% CI 1.82-3.85), and preterm birth at less than 37 weeks of gestation (11.0% compared with 4.7%; adjusted OR 2.50, 95% CI 1.86-3.37) compared with the comparison group. Human immunodeficiency virus-infected women who received HAART had a significantly higher risk of preeclampsia compared with women without HIV (13.0% compared with 4.1%; adjusted OR 3.52, 95% CI 2.51-4.94) and compared with the non-HAART group (13.0% compared with 4.6%; adjusted OR 3.08, 95% CI 1.34-5.07). The non-HAART group had a similar risk compared with women without HIV (4.6% compared with 4.1%; adjusted OR 1.14, 95% CI 0.53-2.44).CONCLUSION:Human immunodeficiency virus-infected women had an increased risk of preeclampsia. Some of this risk seems to be linked to HAART.
引用
收藏
页码:1027 / 1032
页数:6
相关论文
共 50 条
  • [1] Safety and Efficacy of Fosamprenavir in Human Immunodeficiency Virus-infected Pregnant Women
    Martorell, Claudia
    Theroux, Eileen
    Bermudez, Arlene
    Garb, Jane
    Kronschnabel, Debra
    Oie, Katrina
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (10) : 985 - 985
  • [2] TREATMENT OPTIONS FOR HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PREGNANT-WOMEN
    SPERLING, RS
    STRATTON, P
    [J]. OBSTETRICS AND GYNECOLOGY, 1992, 79 (03): : 443 - 448
  • [3] Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women
    Unadkat, Jashvant D.
    Wara, Diane W.
    Hughes, Michael D.
    Mathias, Anita A.
    Holland, Diane T.
    Paul, Mary E.
    Connor, James
    Huang, Sharon
    Nguyen, Bach-Yen
    Watts, D. Heather
    Mofenson, Lynne M.
    Smith, Elizabeth
    Deutsch, Paul
    Kaiser, Kathleen A.
    Tuomala, Ruth E.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (02) : 783 - 786
  • [4] Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women
    McGowan, JP
    Crane, M
    Wiznia, AA
    Blum, S
    [J]. OBSTETRICS AND GYNECOLOGY, 1999, 94 (05): : 641 - 646
  • [5] Codon 215 mutations in human immunodeficiency virus-infected pregnant women
    Kully, C
    Yerly, S
    Erb, P
    Kind, C
    Krautheim, A
    Perrin, L
    Rudin, C
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (03): : 705 - 708
  • [6] Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women -: In reply
    McGowan, JP
    Crane, M
    Wiznia, AA
    Blum, S
    [J]. OBSTETRICS AND GYNECOLOGY, 2000, 95 (04): : 636 - 637
  • [7] Outcomes in human immunodeficiency virus-infected pregnant women treated with protease inhibitors
    Einstein, FH
    Wright, R
    Trentacoste, S
    Chazotte, C
    Merkatz, IR
    Bernstein, PS
    [J]. OBSTETRICS AND GYNECOLOGY, 2004, 103 (04): : 24S - 24S
  • [8] Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites
    Read, Jennifer S.
    Cahn, Pedro
    Losso, Marcelo
    Pinto, Jorge
    Joao, Esau
    Duarte, Geraldo
    Cardoso, Edmundo
    Freimanis-Hance, Laura
    Stoszek, Sonia K.
    [J]. OBSTETRICS AND GYNECOLOGY, 2007, 109 (06): : 1358 - 1367
  • [9] A retrospective analysis of adverse perinatal outcomes in human immunodeficiency virus-infected pregnant women
    Burke, Charlotte V.
    Tuuli, Methodius
    Basanta-Henry, Patrice
    Duong, Ninh
    Linay, Michael
    [J]. OBSTETRICS AND GYNECOLOGY, 2008, 111 (04): : 80S - 80S
  • [10] Vaginal infections in human immunodeficiency virus-infected women
    Helfgott, A
    Eriksen, N
    Bundrick, CM
    Lorimor, R
    Van Eckhout, B
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (02) : 347 - 353